Erasca, Inc.
37 articles with Erasca, Inc.
-
Erasca Reports First Quarter 2022 Financial Results and Business Updates
5/12/2022
Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2022, and provided business updates.
-
Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
5/3/2022
Erasca, Inc. today announced its participation in the Bank of America Securities 2022 Healthcare Conference.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Erasca Appoints Jean Liu to its Board of Directors
4/27/2022
Erasca, Inc. announced the appointment of Jean Liu to its board of directors and to its audit committee.
-
Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
4/12/2022
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced preclinical data from six poster presentations at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.
-
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
4/6/2022
Erasca, Inc. announced that it will host an investor event on therapeutic opportunities in cancers driven by the RAS/MAPK pathway on Tuesday, April 12 at 4:30 PM Eastern Time.
-
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
3/24/2022
Erasca, Inc. reported financial results for the fiscal quarter ended December 31, 2021, and provided business updates.
-
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
3/10/2022
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for Lilly’s anti-EGFR antibody cetuximab (ERBITUX®).
-
Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
3/8/2022
Erasca, Inc. announced the company will present six poster presentations at the upcoming American Association for Cancer Research Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.
-
Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
2/3/2022
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day.
-
Erasca Strengthens Leadership Team with Two Key Executive Appointments
1/18/2022
Erasca, Inc. today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research.
-
Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Erasca, Inc. today announced its participation in the 40th annual J.P. Morgan Healthcare Conference. of the company and pipeline at 3:45 pm Eastern Time on Monday, January 10, 2022.
-
23andMe, EQRx Lead IPO Rush in 2021
12/21/2021
The year kicked off with a bang as multiple companies raced to a public listing. -
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
12/17/2021
Erasca, Inc. today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-801.
-
Erasca Added to the Nasdaq Biotechnology Index
12/14/2021
Erasca, Inc. today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
-
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
11/16/2021
Erasca, Inc. today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a “Fireside Chat” beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021.
-
Erasca Reports Third Quarter 2021 Financial Results and Business Updates
11/10/2021
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended September 30, 2021, and provided business updates.
-
Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
10/25/2021
Erasca, Inc. (Nasdaq: ERAS), today announced the presentation of preclinical data for ERAS-801, a small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of glioblastoma multiforme (GBM), at the American Association for Cancer Research (AACR) Special Virtual Conference on Brain Cancer.
-
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.